A randomized trial of consolidation-targeted adjuvant therapy with encorafenib and cetuximab versus usual care for patients with stage II/III BRAF V600E colon cancer: Alliance for Clinical Trials in Oncology A022004.

Authors

Rona Yaeger

Memorial Sloan Kettering Cancer Center, New York, NY

Rona Yaeger , Qian Shi , Amylou C. Dueck , Elie G. Dib , Syed Mohammad Ali Kazmi , Olatunji B. Alese , Smitha S. Krishnamurthi , Andrew B. Nixon , Ardaman Shergill , Eileen Mary O'Reilly , Jeffrey A Meyerhardt

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2017 ASCO Annual Meeting

bookmark_border

Association of prognostic value of primary tumor location in stage III colon cancer with RAS and BRAF mutational status.

First Author: Julien Taieb

insert_chart_outlined

Poster

2022 ASCO Gastrointestinal Cancers Symposium

bookmark_border

BREAKWATER: Randomized phase 3 study of encorafenib (enco) + cetuximab (cet) ± chemotherapy for first-line treatment (tx) of BRAF V600E-mutant (BRAFV600) metastatic colorectal cancer (mCRC).

First Author: Scott Kopetz

insert_chart_outlined

Poster

2021 ASCO Annual Meeting

bookmark_border

BREAKWATER: Randomized phase 3 study of encorafenib (enco) + cetuximab (cetux) ± chemotherapy for first-line (1L) treatment (tx) of BRAF V600E-mutant (BRAF^V600E) metastatic colorectal cancer (mCRC).

First Author: Scott Kopetz

insert_chart_outlined

Poster

2021 ASCO Annual Meeting

bookmark_border

Association of plasma adiponectin with tumor infiltrating lymphocytes and survival in patients with stage III colon cancer (NCCTG N0147; Alliance).

First Author: Frank A. Sinicrope